

VICURON PHARMACEUTICALS INC

Form 8-K

July 20, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):

July 19, 2004

Vicuron Pharmaceuticals Inc.

(Exact Name of Registrant As Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-31145
(Commission File Number)

04-3278032
(I.R.S. Employer
Identification Number)

455 South Gulph Road, Suite 305, King of Prussia, PA 19406

Edgar Filing: VICURON PHARMACEUTICALS INC - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

(610) 205-2300

(Registrant's telephone number, including area code)

not applicable

(Former Name or Former Address, if Changed Since Last Report.)

Item 5. Other Events and Required FD Disclosure.

On July 19, 2004, Oscient Pharmaceuticals Corporation announced that it closed enrollment in its study of the prevention of vancomycin-resistant enterococci (VRE) bloodstream infections (the so-called RAVE (Ramoplanin Against VRE) trial). Oscient took this action without the consent of Vicuron Pharmaceuticals Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VICURON PHARMACEUTICALS INC.
(Registrant)

Date: July 20, 2004

By: /s/ GEORGE F. HORNER III

George F. Horner III
President and Chief Executive Officer